KLF2 is identified as a required mediator for statin-induced eNOS and thrombomodulin expression in endothelial cells, presenting a potential therapeutic target for vascular disease.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for KLF2 as statin mediator in endothelial cells; does not support clinical translation.
Taken together, these observations indicate that statin-dependent induction of eNOS and thrombomodulin requires KLF2 and thereby provides a novel molecular target for modulating endothelial function in vascular disease.
No takes yet. Share an insight, caveat, or question.
SenBanerjee et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: